France-based Inotrem SA has appointed Martin Koch as chief operating officer to help the company execute its business plan for anti-inflammatory compounds led by a product for septic shock. He comes from Genticel SA where as chief financial officer, he led the company’s initial public share offering and subsequent merger with GenKyoTex SA in 2017. He has also worked in Europe for Eli Lilly and Co, Elan Pharmaceuticals and Cephalon (now Teva Pharmaceutical Industries Ltd).
Inotrem announced the appointment on 18 January 2018.
Copyright 2018 Evernow Publishing Ltd